A phase III trial (extended adjuvant treatment of breast cancer with neratinib, ExteNET) showed that neratinib significantly improved 5-year invasive disease-free survival (iDFS) in EBC patients, who completed trastuzumab-based adjuvant therapy.133,138 A combination of doublet anti-HER2 therapy, i.e., neratinib and trastuzumab plus paclitaxel, was evaluated in a phase I/II study. The gene discussed is ERBB2; the disease is breast cancer.